All In Biotech

Drug Trial Radar · NCT02631044

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

387

Actual

Start

Jan 6, 2016

Primary completion

May 16, 2024

Study completion May 16, 2024

Sponsor

Lead sponsor
Juno Therapeutics, a Subsidiary of CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.

Conditions

  • Non-Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Mantle-cell Lymphoma
  • Primary Mediastinal B-cell Lymphoma

Interventions

  • JCAR017 (lisocabtagene maraleucel) single-dose scheduleBiological

    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

  • JCAR017 (lisocabtagene maraleucel) 2-dose scheduleBiological

    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-related adverse events (AEs) as assessed by CTCAE v4.03Time frame: Up to 730 days after the final JCAR017 infusion
  2. Dose-limiting toxicities of JCAR017Time frame: 28 days after first (single-dose schedule) or second (2-dose schedule) JCAR017 infusion
  3. Objective response rate (ORR)Time frame: 24 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0006

    Birmingham, Alabama

  • Local Institution - 0007

    Duarte, California

  • Local Institution - 0010

    San Francisco, California

  • Local Institution - 0020

    Aurora, Colorado

  • Local Institution - 0019

    Atlanta, Georgia

  • Local Institution - 0003

    Chicago, Illinois

  • Local Institution - 0005

    Boston, Massachusetts

  • Local Institution - 0015

    Boston, Massachusetts

  • Local Institution - 0008

    Omaha, Nebraska

  • Local Institution - 0001

    New York, New York

  • Local Institution - 0021

    Charlotte, North Carolina

  • Local Institution - 0029

    Pittsburgh, Pennsylvania

  • Local Institution - 0002

    Houston, Texas

  • Local Institution - 0018

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.